A lot of insider buying in Dendreon lately, Directors, Officers, CEO, Cheif Scientific Officer among others. I bought some this morning at $5.70. DNDN has $3.21 cash per share, virtually no debt and a lot of good science to go along with substantial insider buying at these levels.
From Yahoo:
Dendreon Corporation is a biotechnology company focused on the discovery, development and commercialization of targeted therapies for cancer. The Company's portfolio includes product candidates to treat a range of cancers using therapeutic vaccines, monoclonal antibodies, small molecules and pro-drugs. Its most advanced product candidate is Provenge, a therapeutic vaccine for the treatment of prostate cancer. Provenge is being evaluated under a pivotal, randomized, double blind, placebo-controlled Phase III clinical trial in men with androgen independent prostate cancer whose cancer has a Gleason score of seven and less. Dendreon's preclinical programs include monoclonal antibodies, therapies targeting the trp-p8 pathway and serine protease and pro-drug product candidates for the treatment of cancer. In July 2003, Dendreon completed its acquisition of Corvas International, Inc.
Wednesday, March 23, 2005
Thursday, March 10, 2005
Friday, March 04, 2005
BI-Buy
Stock: TELIK
Symbol: TELK
I-BUY: Director, $181K, 10K shares @ $18.08
SEC Filed: Friday, March 4, 2005 @ 16:05 (4:05PM EDT)
BI-BUY: Biotech Insider Buy
Telik, Inc. is a biopharmaceutical company that discovers, develops and commercializes small molecule drugs to treat serious diseases. The Company discovered all of its product candidates using its proprietary technology, Target-Related Affinity Profiling (TRAP). The technology exploits a fundamental property of all drugs, which is their selective interactions with proteins. By developing a profile of how small molecule chemicals interact with a reference panel of proteins, the Company may identify compounds active against disease-related protein targets much faster than by alternative technologies. The Company concentrates its efforts on three therapeutic areas: cancer, diabetes and inflammatory diseases.
Symbol: TELK
I-BUY: Director, $181K, 10K shares @ $18.08
SEC Filed: Friday, March 4, 2005 @ 16:05 (4:05PM EDT)
BI-BUY: Biotech Insider Buy
Telik, Inc. is a biopharmaceutical company that discovers, develops and commercializes small molecule drugs to treat serious diseases. The Company discovered all of its product candidates using its proprietary technology, Target-Related Affinity Profiling (TRAP). The technology exploits a fundamental property of all drugs, which is their selective interactions with proteins. By developing a profile of how small molecule chemicals interact with a reference panel of proteins, the Company may identify compounds active against disease-related protein targets much faster than by alternative technologies. The Company concentrates its efforts on three therapeutic areas: cancer, diabetes and inflammatory diseases.
Wednesday, March 02, 2005
Inside Straight - March 2, 2005
Stock: MCDT
Insider Buy Posted at SEC Analytics: 11:02am
Price Available at Time of Posting: $3.60
Closing Price: $4.03
Intra-day Return: 12%
Stock: CTLM
Insider Buy Posted at SEC Analytics: 2:15pm
Price Available at Time of Posting: $2.00
Closing Price: $2.15
Intra-day Return: 7.5%
Insider Buy Posted at SEC Analytics: 11:02am
Price Available at Time of Posting: $3.60
Closing Price: $4.03
Intra-day Return: 12%
Stock: CTLM
Insider Buy Posted at SEC Analytics: 2:15pm
Price Available at Time of Posting: $2.00
Closing Price: $2.15
Intra-day Return: 7.5%
Not All Insider Buys Are Created Equal
On February 11, 2005, a Director of Edgar Online bought $27K worth of EDGR on the open market for about $1.41 a share. Two days earlier this Director bought about $2K worth of EDGR for $1.33 a share.
Nothing to write a blog about?
By Valentine's day, the stock was up to $1.75, a tidy 20% move. A week later $2.33. By February 28th, the stock closed at $2.45. Yesterday, March 1, it touched $2.70. Today, EDGR is running, opening at $2.65 and has printed as high as $3.49.
True to my system, I was in and out of EDGR on February 11th, for about a 4% daytrade gain. The other 150% or so of gain was left on the table. There's a lesson here.
If anyone knows what that lesson is, please comment.
Nothing to write a blog about?
By Valentine's day, the stock was up to $1.75, a tidy 20% move. A week later $2.33. By February 28th, the stock closed at $2.45. Yesterday, March 1, it touched $2.70. Today, EDGR is running, opening at $2.65 and has printed as high as $3.49.
True to my system, I was in and out of EDGR on February 11th, for about a 4% daytrade gain. The other 150% or so of gain was left on the table. There's a lesson here.
If anyone knows what that lesson is, please comment.
Subscribe to:
Posts (Atom)